Hydroxychloroquine and the treatment of Sjogren syndrome, chronic ulcerative stomatitis, and oral lichen planus in the age of COVID-19

The Food and Drug Administration has recently approved the off-label use of hydroxychloroquine (HCQ) for the treatment of coronavirus disease 2019 (COVID-19) infections. However, a recent study not only failed to demonstrate HCQ efficacy but also documented a serious side effect of COVID-19 therapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Hussein, Heba, Brown, Ronald
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2021
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7305926/
https://www.ncbi.nlm.nih.gov/pubmed/32654931
http://dx.doi.org/10.1016/j.oooo.2020.06.011

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7305926/
https://www.ncbi.nlm.nih.gov/pubmed/32654931
http://dx.doi.org/10.1016/j.oooo.2020.06.011

Ejemplares similares